The renin-angiotensin-aldosterone system and its suppression

被引:312
作者
Ames, Marisa K. [1 ]
Atkins, Clarke E. [2 ]
Pitt, Bertram [3 ]
机构
[1] Colorado State Univ, Coll Vet Med, Dept Clin Sci, Ft Collins, CO 80523 USA
[2] North Carolina State Univ, Coll Vet Med, Dept Clin Sci, Raleigh, NC USA
[3] Univ Michigan, Sch Med, Dept Med, Ann Arbor, MI 48104 USA
关键词
angiotensin converting enzyme inhibitor; angiotensin receptor blocker; chronic kidney disease; heart failure; mineralocorticoid receptor blocker; proteinuric kidney disease; systemic hypertension; CONGESTIVE-HEART-FAILURE; LEFT-VENTRICULAR DYSFUNCTION; CONVERTING ENZYME-INHIBITION; VASCULAR SMOOTH-MUSCLE; MITRAL-VALVE DISEASE; INDUCED ANP SECRETION; II RECEPTOR BLOCKADE; MAINE-COON CATS; MINERALOCORTICOID RECEPTOR; BLOOD-PRESSURE;
D O I
10.1111/jvim.15454
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Chronic activation of the renin-angiotensin-aldosterone system (RAAS) promotes and perpetuates the syndromes of congestive heart failure, systemic hypertension, and chronic kidney disease. Excessive circulating and tissue angiotensin II (AngII) and aldosterone levels lead to a pro-fibrotic, -inflammatory, and -hypertrophic milieu that causes remodeling and dysfunction in cardiovascular and renal tissues. Understanding of the role of the RAAS in this abnormal pathologic remodeling has grown over the past few decades and numerous medical therapies aimed at suppressing the RAAS have been developed. Despite this, morbidity from these diseases remains high. Continued investigation into the complexities of the RAAS should help clinicians modulate (suppress or enhance) components of this system and improve quality of life and survival. This review focuses on updates in our understanding of the RAAS and the pathophysiology of AngII and aldosterone excess, reviewing what is known about its suppression in cardiovascular and renal diseases, especially in the cat and dog.
引用
收藏
页码:363 / 382
页数:20
相关论文
共 50 条
  • [31] Dual Renin-Angiotensin-Aldosterone Blockade: Promises and Pitfalls
    Chrysant, Steven G.
    Chrysant, George S.
    CURRENT HYPERTENSION REPORTS, 2015, 17 (01) : 1 - 10
  • [32] The renin-angiotensin-aldosterone system and calcium-regulatory hormones
    Vaidya, A.
    Brown, J. M.
    Williams, J. S.
    JOURNAL OF HUMAN HYPERTENSION, 2015, 29 (09) : 515 - 521
  • [33] CONTROL OF BLOOD-PRESSURE BY THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
    HALL, JE
    CLINICAL CARDIOLOGY, 1991, 14 (08) : 6 - 21
  • [34] Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies
    Patel, Seema
    Rauf, Abdur
    Khan, Haroon
    Abu-Izneid, Tareq
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 94 : 317 - 325
  • [35] Future drug discovery in renin-angiotensin-aldosterone system intervention
    Tamargo, Maria
    Tamargo, Juan
    EXPERT OPINION ON DRUG DISCOVERY, 2017, 12 (08) : 827 - 848
  • [36] Dual renin-angiotensin-aldosterone system inhibition: boon or bust?
    Hirsch, S.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 (10) : 1337 - 1340
  • [37] Renin-Angiotensin-Aldosterone System Blockade in Diabetic Nephropathy. Present Evidences
    Lozano-Maneiro, Luz
    Puente-Garcia, Adriana
    JOURNAL OF CLINICAL MEDICINE, 2015, 4 (11) : 1908 - 1937
  • [38] Renin-Angiotensin-Aldosterone System Blockade Effects on the Kidney in the Elderly: Benefits and Limitations
    Turgut, Faruk
    Balogun, Rasheed A.
    Abdel-Rahman, Emaad M.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (07): : 1330 - 1339
  • [39] Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?
    Chen, Shan Shan
    Seliger, Stephen L.
    Fried, Linda F.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2014, 23 (05) : 449 - 455
  • [40] The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure
    Pugliese, Nicola Riccardo
    Masi, Stefano
    Taddei, Stefano
    HEART FAILURE REVIEWS, 2020, 25 (01) : 31 - 42